Cargando…

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts

BACKGROUND: Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multice...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lantero-Rodriguez, Juan, Vrillon, Agathe, Fernández-Lebrero, Aida, Ortiz-Romero, Paula, Snellman, Anniina, Montoliu-Gaya, Laia, Brum, Wagner S., Cognat, Emmanuel, Dumurgier, Julien, Puig-Pijoan, Albert, Navalpotro-Gómez, Irene, García-Escobar, Greta, Karikari, Thomas K., Vanmechelen, Eugeen, Ashton, Nicholas J., Zetterberg, Henrik, Suárez-Calvet, Marc, Paquet, Claire, Blennow, Kaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999575/ https://www.ncbi.nlm.nih.gov/pubmed/36899441 http://dx.doi.org/10.1186/s13195-023-01201-0

Ejemplares similares

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
por: Lantero‐Rodriguez, Juan, et al.
Publicado: (2021)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2023)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
por: Yu, Lei, et al.
Publicado: (2023)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
por: Mundada, Nidhi S., et al.
Publicado: (2023)

N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
por: Snellman, Anniina, et al.
Publicado: (2022)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
por: Brickman, Adam M., et al.
Publicado: (2021)

Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
por: Doré, Vincent, et al.
Publicado: (2022)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
por: Montoliu-Gaya, Laia, et al.
Publicado: (2023)

Long-Term Depression-Inducing Low Frequency Stimulation Enhances p-Tau181 and p-Tau217 in an Age-Dependent Manner in Live Rats
por: Zhang, Yangyang, et al.
Publicado: (2022)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Measurement of \tau -> 3 \pi \nu _\tau branching ratio and P _\tau with the DELPHI detector
por: DELPHI Collaboration
Publicado: (2018)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Measurement of $\sigma(p\overline{p}\to Z).Br(Z\to\tau^{+}\tau^{-})$ and search for Higgs bosons decaying to $\tau^{+}\tau^{-}$ at $\sqrt{s} = 1.96 TeV$
por: Galea, Cristina Florina
Publicado: (2008)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

Simple, Single-Shot Phosphoproteomic Analysis of Heat-Stable Tau Identifies Age-Related Changes in pS235- and pS396-Tau Levels in Non-human Primates
por: Leslie, Shannon N., et al.
Publicado: (2021)

P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
por: Wesenhagen, Kirsten E. J., et al.
Publicado: (2022)

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2020)

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2022)

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020)

Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic Mice
por: Ozcelik, Sefika, et al.
Publicado: (2013)

T-Tau and P-Tau in Brain and Blood from Natural and Experimental Prion Diseases
por: Rubenstein, Richard, et al.
Publicado: (2015)

Tau neutrino physics at SHiP
por: DE LELLIS, Giovanni
Publicado: (2015)

Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in Tau(P301L)-BiFC mice
por: Lim, Sungsu, et al.
Publicado: (2023)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3vhn0dht247mrma7oa8ei787ft